2023 Nov 1 -15 SITC 2023 (poster 381)

SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function


  • Phase 1 clinical outcomes indicate; 1) pristine safety in all 28 end-stage cancer patients treated with SUPLEXA cells, 2) Complete or partial responses in MSI-Hcolorectal cancer patients and stable disease in renal cell carcinoma and melanoma patients.
  • Immunomodulation of blood activated classical monocytes and PMN-MDSCs in CRC patients showing beneficial clinical responses to SUPLEXA therapeutic cells.
  • Circulating cytokines and biomarkers are significantly modulated by SUPLEXA cell treatments.